Chelsea Johnson is a biotech venture capital investor and company builder with extensive experience in the life sciences sector. They currently serve as a Board Observer for Scorpion Therapeutics, Lifordi Immunotherapeutics, Rectify Pharma, Judo Bio, and K36 Therapeutics, as well as the Head of New Ventures at Biogen. Chelsea has previously held roles as a Senior Associate and Principal at Atlas Venture, and worked as an Associate Director in Business Development and Strategy at Tango Therapeutics. They obtained a BA in Biology from Dartmouth College and are pursuing a PhD in Biological Chemistry and Molecular Pharmacology from Harvard University.
This person is not in the org chart
This person is not in any teams
This person is not in any offices